Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Interval cancer (IC) is an important quality indicator in colorectal cancer (CRC) screening. Previously, we found that fecal immunochemical test (FIT) ICs are more common in women, older age, right-sided tumors, and advanced stage. Here, we extended our existing stage IV patient cohort with clinicopathological and molecular characteristics, to identify factors associated with FIT-IC.
Methods: Logistic regression models were fit to identify variables associated with the odds of having a stage IV FIT-IC. Multivariate models were corrected for gender, age, and location.
Results: A total of 292 screen-detected (SD) CRCs and 215 FIT-IC CRCs were included. FIT-IC CRC had 5 fold higher odds to be a neuroendocrine (NET) tumor and 2.5 fold higher odds to have lymphovascular invasion. Interestingly, some variables lost significance upon accounting for location. Thus, tumor location is a critical covariate that should always be included when evaluating factors related to FIT-IC.
Conclusions: We identified NETs and lymphovascular invasion as factors associated with increased odds of having a stage IV FIT-IC. Moreover, we highlight the importance of tumor location as a covariate in evaluating FIT-IC related factors. More research across all stages is needed to clarify how these insights might help to optimize the Flemish CRC screening program.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11402608 | PMC |
| http://dx.doi.org/10.3389/fonc.2024.1409196 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathological features of dermal clear cell sarcoma: A series of 13 cases.
Pathol Res Pract
September 2025
Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China. Electronic address:
Background: Dermal clear cell sarcoma (DCCS) is a rare malignant mesenchymal neoplasm. Owing to the overlaps in its morphological and immunophenotypic profiles with a broad spectrum of tumors exhibiting melanocytic differentiation, it is frequently misdiagnosed as other tumor entities in clinical practice. By systematically analyzing the clinicopathological characteristics, immunophenotypic features, and molecular biological properties of DCCS, this study intends to further enhance pathologists' understanding of this disease and provide a valuable reference for its accurate diagnosis.
View Article and Find Full Text PDFMulticenter Development of a Clinical-Molecular Nomogram for Predicting Survival in Lung Cancer Brain Metastasis Patients.
Cancer Manag Res
September 2025
The School of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
Background: Lung cancer brain metastasis (LCBM) accounts for 40-50% of intracranial malignancies, with emerging evidence of alternative metastatic pathways circumventing the blood-brain barrier. Existing prognostic models lack validation in Asian populations and molecular stratification. This multicenter study aimed to develop a clinical nomogram integrating clinicopathological and molecular determinants for personalized LCBM management.
View Article and Find Full Text PDFIGL::CCND1 detected by optical genome mapping revises diagnosis of a B-cell lymphoma.
Am J Clin Pathol
September 2025
Laboratory for Clinical Genomics and Advanced Technology (CGAT)-Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States.
Objective: Differentiating between the repertoire of immunoglobulin rearrangements is important in guiding diagnoses and management of B-cell lymphoma processes. A subset of these disease entities, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), can show distinct genomic profiles with a shared cell of origin. In this report, we describe a rare case in which differentiating between the immunoglobulin family of rearrangements (IGH, IGK, IGL) with optical genome mapping (OGM) helped revise the clinical suspicion of CLL.
View Article and Find Full Text PDFFusion-Negative Rhabdomyosarcoma: Clinical Application of Targeted RNA Sequencing.
Pediatr Dev Pathol
September 2025
The Hospital for Sick Children, Division of Pathology, Toronto, Canada.
Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. For stratification purposes, rhabdomyosarcoma is classified into fusion-positive RMS (alveolar rhabdomyosarcoma) and fusion-negative RMS (embryonal or spindle cell/sclerosing, FN-RMS) subtypes according to its fusion status. This study aims to highlight the pathologic and molecular characteristics of a cohort of FN-RMS using a targeted NGS RNA-Seq assay.
View Article and Find Full Text PDFSilencing Calumenin Expression via Artificial MicroRNA, a Potential Breakthrough for Inhibiting Proliferation, Halting Migration, and Triggering Apoptosis in Breast Cancer Cells.
Adv Pharm Bull
July 2025
Department of Molecular Medicine, Institute of Medical Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Purpose: Calumenin (CALU) is a calcium-binding protein involved in several physiological processes, exhibiting tumor-specific expression variation and emerging as a potential player in cancer progression. This study aimed to investigate the correlation between CALU and clinicopathological features in breast cancer (BC) and perform a functional assessment of CALU based on a microRNA-mediated knockdown approach.
Methods: The BC tissues' CALU expression was measured by q-RT-PCR.